Regenerative Therapies to Restore Interneuron Disturbances in Experimental Models of Encephalopathy of Prematurity

Josine E G Vaes1,2, Chantal M Kosmeijer1, Marthe Kaal1

  • 1Department for Developmental Origins of Disease, University Medical Center Utrecht Brain Center and Wilhelmina Children's Hospital, Utrecht University, 3584 Utrecht, The Netherlands.

Insights

Encephalopathy of Prematurity (EoP) causes interneuron development issues in preterm neonates. Intranasal mesenchymal stem cells (MSCs) and insulin-like growth factor I (IGF1) show promise in restoring these critical brain cells and improving social behavior.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Neonatal Medicine

Background:

  • Encephalopathy of Prematurity (EoP) is a significant cause of morbidity in preterm infants.
  • Research is shifting focus from oligodendrocyte maturation to interneuron developmental disturbances in EoP.
  • Understanding interneuron abnormalities is crucial for developing effective EoP treatments.

Purpose of the Study:

  • To investigate interneuron abnormalities in experimental models of EoP.
  • To explore the therapeutic potential of intranasal mesenchymal stem cells (MSCs) and insulin-like growth factor I (IGF1) in restoring interneuron development.
  • To assess the impact of EoP and potential therapies on social behavior.

Main Methods:

  • Two experimental models of EoP were established in rats and mice, involving fetal inflammation and/or postnatal hypoxia/ischemia.
  • Cortical and hippocampal interneuron populations (total and specific subtypes like PV+, VIP+, SST+) were quantified.
  • Behavioral tests, specifically social behavior, were conducted.
  • Treatment strategies involving intranasal MSCs and IGF1 were administered.

Main Results:

  • Rat models showed transient increases in total interneurons but deficits in parvalbumin (PV)+ interneurons and long-term deficits in hippocampal interneurons.
  • Mouse models exhibited transient reductions in PV+ interneurons and long-lasting increases in vasoactive intestinal polypeptide (VIP)+ cells, with deficits in somatostatin (SST)+ cells.
  • Both MSC and IGF1 therapies largely restored interneuron abnormalities in EoP mice.
  • EoP-associated impaired social behavior was partially ameliorated by the therapies.

Conclusions:

  • Experimental EoP induces model-specific interneuron developmental disturbances.
  • Intranasal MSCs and IGF1 represent promising therapeutic strategies for addressing interneuron deficits in EoP.
  • Restoring interneuron development may improve neurological outcomes and behavior in EoP.